Skip to main content

The Cell-Kill Paradigm: Bleak Outcomes

  • Chapter
  • First Online:
The Conquest of Cancer
  • 819 Accesses

Abstract

What has the cell-kill paradigm and its dominance of cancer research, diagnosis, treatment, and outcome assessment achieved in the context of the “War on Cancer” since the enactment of the National Cancer Act of 1971? The answer will vary depending on how achievement is measured and who does the assessment. For example, in a 1996 review article titled The war on cancer [505] marking the 25th birthday of the National Cancer Act of 1971, the author used a quote from Charles Dickens to dramatize its failure: “Dead, your Majesty. Dead, my lords and gentlemen. Dead, right reverends and wrong reverends of every order. Dead, men and women, born with Heavenly compassion in your hearts. And dying thus around us every day”. Less than a year later, an editorial written by a former Director of the NCI rejoiced “Happy birthday ‘War’, you deserve a pat on the back” [506]. Both authors converged on crediting major scientific advances made during this period, especially the breathtaking advances in molecular biology and molecular genetics, including the genome project, that have revolutionized our knowledge about cancer. Yet, while both see a brighter future after these advances are applied to the practice of medicine, the former author concluded, “We must develop new approaches to control this plague of deaths, adopting an ethic of prevention ….to prevent disease before it becomes invasive and metastatic” [507].

Insanity: doing the same thing over and over again and expecting different results.

– Albert Einstein

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Drugs targeting rare diseases.

References

  1. Sporn MB. The war on cancer. Lancet 1996;347:1377–1381.

    Article  CAS  PubMed  Google Scholar 

  2. DeVita VT. The War on cancer has a birthday, and a present. J Clin Oncol 1997;15:867–869.

    PubMed  Google Scholar 

  3. Sporn MB. Op. cit.

    Google Scholar 

  4. Jemal A, Ward E, Thun M () Declining Death Rates Reflect Progress against Cancer. PLoS ONE 2010;5:e9584. doi:10.1371/journal.pone.0009584

    Article  PubMed Central  PubMed  Google Scholar 

  5. Kantarjian H. The Price of Drugs for Chronic Myeloid Leukemia (CML); A Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts. Blood 2013;121:4439–4442.

    Article  PubMed Central  Google Scholar 

  6. Bach PB. Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs. N Engl J Med 2009;360:626–633.

    Article  CAS  PubMed  Google Scholar 

  7. Kantarjian H. Op. cit.

    Google Scholar 

  8. Bailar JC, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569–1574.

    Article  PubMed  Google Scholar 

  9. Faguet GB. The War on Cancer. Op. cit.

    Google Scholar 

  10. World Oncology Forum: Are we winning the war on cancer? Web 1 June 2013. http://www.eso.net/varie/wof.html

  11. Cavalli F. An appeal to world leders. Lancet 2013;381:425–426.

    Article  PubMed  Google Scholar 

  12. STOP CANCER NOW! On this World Cancer Day 2013, participants of the World Oncology Forum raise the alarm about the increasing devastation caused by cancer across the world. Web 1 Jun 2013. www.eso.net/images/Allegati/statementenglish.pdf

  13. Sustaining progress against cancer in an era of cost containment: Discussion Paper. Kean M, Lessor T. (Eds). Cambriidge, MA: Feinstein Kean Healthcare; June 2012. Web 16 Jul. 2013. http://turningthetideagainstcancer.org/sustaining-progress-discussion-paper.pdf

  14. SEER Cancer statistics: Breast, Table 4:11 Op. cit.

    Google Scholar 

  15. Special Report: Measurement of Progress Against Cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst 1990;82:825–835.

    Google Scholar 

  16. Wu J, Josepj SO, Muggia FM. Targeted Therapy: Its Status and Promise in Selected Solid Tumors, Part I. Oncology 2012;26:1–12.

    Article  CAS  Google Scholar 

  17. Cancer Statistics 2013: A prsentation from the American Cancer Society. Web 3 Sept. 2013. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/cancer-statistics-2013-slide-presentation.pdf

  18. Cancer Facts & Fcer igures: American Cancer Society. Web 20 Jan. 2013. http://www.cancer.org/acs/groups/content/@nho/documents/document/2008cafffinalsecuredpdf.pdf

  19. Cancer Trends, Progress Report: 2011/2012. Web 20 Jan. 2013. http://progressreport.cancer.gov/highlights.asp

  20. Andersen LD, Remington P, Trentham-Dietz A, et al. Assessing a decade of progress in cancer control. The Oncologist 2002;7:200–204.

    Article  PubMed  Google Scholar 

  21. Kuenstner S, Langelotz C, Budach V, et al. The comparability of quality of life scores. a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Eur J Cancer 2002;38:339–48.

    Article  CAS  PubMed  Google Scholar 

  22. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458–1460.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Kiebert G, Wait S, Beernhard J, et al. Practice and Policy of measuring quality of life and health economics in cancer trials: A survey among co-operative trial groups. Qual Life Res 2000;9:1073–1080.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Faguet, G. (2015). The Cell-Kill Paradigm: Bleak Outcomes. In: The Conquest of Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9165-6_9

Download citation

Publish with us

Policies and ethics